HAW PAR CORP LTD (H02) fair value: what the stock is really worth
We calculate from audited financials what HAW PAR CORP LTD is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
HAW PAR CORP LTD
H02 · SGStretched ValuationStrong overvaluation with only moderate quality.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 19, 2026.
How to read this chart
60‑month range 7.35 SGD – 18.05 SGD · fair‑value band 7.24 SGD – 10.36 SGD · the 13.26 SGD price screens above the 8.53 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 19, 2026.
Company profile
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally.
Show more
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally. It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties. In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums. Further, the company is involved in the property development; and owning and letting properties; letting out of office spaces; and management support services. Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.
Stock analysis
HAW PAR CORP LTD (H02) currently trades at 13.26 SGD, while our model-based Fair Value estimate is 8.53 SGD, implying the stock looks roughly 55.4% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 22.58 SGD per share, and 8 of the 24 models we run sit above the 13.26 SGD price.
Bear case: the Economic Profit group reads lowest at 6.06 SGD, and 16 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 7.24 SGD (bear) to 10.36 SGD (bull), the price of 13.26 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
HAW PAR CORP LTD reported revenue of 230M SGD in FY2025 versus 141M SGD in FY2021, a compound +13.0%/yr. Reported net income was 265M SGD in FY2025, compounding +24.6%/yr from FY2021.
Key figures
Market cap 3.5B SGD (≈ $2.8B) · P/E ratio 11.1 · P/S ratio 12.8 · EPS (TTM) 1.20 SGD · Dividend yield 3.0% · Net margin 115% · Return on equity 6.3% · Return on assets (EBIT) 1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −36%, H02 screens richer than that median.
Fair Value models
All 24 models by family
Notify me when H02 reaches fair value
Put H02 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 46
Revenue & earnings trend
Growth Forecast
H02 screens 55% overvalued. Compare with Eli Lilly and Company →
Compare HAW PAR CORP LTD with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Valuation of the Singapore market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $778.94 | −31% |
| Johnson & Johnson, JNJ | $267.20 | $169.04 | −37% |
| AbbVie Inc ABBV | $263.04 | $259.66 | −1% |
| Roche Holding RO | CHF 369.80 | CHF 306.54 | −17% |
| Merck & Co MRK | €124.22 | €101.89 | −18% |
| Novartis AG NVS | $137.16 | $138.70 | +1% |
| Novo Nordisk A/S NOVOB | kr 272.60 | kr 409.46 | +50% |
| Amgen Inc AMGN | $375.65 | $413.22 | +10% |
| Gilead Sciences, Inc GILD | $146.30 | $198.51 | +36% |
| Pfizer Inc PFE | $27.55 | $20.39 | −26% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is HAW PAR CORP LTD (H02) overvalued or undervalued?
What is the fair value of H02?
What is the quality score of H02?
What is the price target for HAW PAR CORP LTD (H02)?
What is the HAW PAR CORP LTD stock forecast for 2026?
What is the revenue of HAW PAR CORP LTD (H02)?
Does HAW PAR CORP LTD pay a dividend?
What growth is priced into HAW PAR CORP LTD (H02)?
What discount rate (WACC) does the fair value of H02 use?
What is a reverse DCF?
How much growth has HAW PAR CORP LTD (H02) delivered so far?
How fast is the sector of HAW PAR CORP LTD (H02) growing?
What is the free cash flow yield of HAW PAR CORP LTD (H02)?
What is the intrinsic value of HAW PAR CORP LTD (H02)?
Is HAW PAR CORP LTD stock overvalued or undervalued in 2026?
Is fair value the same as the market price of H02?
How much is HAW PAR CORP LTD worth?
What do the bullish and bearish scenarios say about H02?
What is the P/E ratio of H02?
How solid is the balance sheet of HAW PAR CORP LTD (H02)?
How far is H02 from its 52-week high?
Which stocks are comparable to HAW PAR CORP LTD?
Is HAW PAR CORP LTD stock attractive at the current price?
How is the fair value of H02 calculated?
Is it still worth investing in stocks now?
What is the share price of HAW PAR CORP LTD (H02)?
What should I pay attention to with HAW PAR CORP LTD right now?
Key figures of HAW PAR CORP LTD
How large is the market capitalisation of HAW PAR CORP LTD (H02)?
What is the P/S ratio of HAW PAR CORP LTD (H02)?
What are the earnings per share of HAW PAR CORP LTD (H02)?
What is the dividend yield of HAW PAR CORP LTD (H02)?
What is the net margin of HAW PAR CORP LTD (H02)?
What is the return on equity of HAW PAR CORP LTD (H02)?
What is the EBIT return on assets of HAW PAR CORP LTD (H02)?
What is the operating margin of HAW PAR CORP LTD (H02)?
How fast is revenue growing at HAW PAR CORP LTD (H02)?
How fast are earnings growing at HAW PAR CORP LTD (H02)?
Watch HAW PAR CORP LTD in the live analysis
One click puts HAW PAR CORP LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.